Tumor cells exhibit a resistance-associated secretory phenotype involving extracellular vesicles (EVs) and heat shock proteins (HSPs). This response occurs in response to cell stress and cancer therapeutics.
Introduction
Tumor cells are often exposed to various stresses such as immune/inflammatory stress, therapeutics [1] , hypoxia, acidification, oxidative stress [2, 3] , starvation [4] , nutrient stress [5] , heat and cold [6, 7] , thermal stress, replication stress [8] , endoplasmic reticulum (ER) stress, neurotoxic stress [9] , genotoxic (DNA damage) [10] and proteotoxic stress [11, 12] . Heat shock proteins (HSPs) were originally found to be induced upon heat shock stress (HSS) {Murshid, 2013, Stress proteins in aging and life span}. Later studies have revealed that other types of stresses can also induce HSPs, including hypoxia [13] and nutrient starvation [4] . HSPs are molecular chaperones that assist in proper protein folding and re-folding in the cells, playing stress-resistant roles in anti-apoptotic activity [6] against radiation therapy, chemotherapy, and immunotherapy. It has been shown that HSPs are often increased in tumor cells and are involved in the properties of tumor progression such as increased migration, invasion, and metastasis [14, 15] . In addition, extracellular HSPs have been shown to be released from cells with vesicles as well as in free form [16] [17] [18] . Notably, it has been shown that HSPs and vesicles were co-released upon cell stress and cell damage such as molecular targeted therapeutic stress [19, 20] , anti-cancer therapeutic DNA damage stress [21, 22] , and HSS [23, 24] . Extracellular HSPs have been also known as alarmin or damage-/ danger-associated molecular patterns (DAMP) that are released from cells upon tissue damage [25, 26] .
Extracellular vesicles (EVs) are particles surrounded by lipid membranes, containing a variety of molecular cargos such as proteins, small and large RNAs, DNA, lipid, glycans, minerals, and metabolites that are secreted by cells [27] [28] [29] [30] . Earlier studies classified the range of EVs into exosomes (50-200 nm) , ectosomes (100-500 nm; also known as microvesicles) [31, 32] , and apoptotic bodies (1-10 μm) based on their mechanisms of generation and release, while additional types of EVs have been reported consisting of oncosomes (named after oncogenic EVs) [33, 34] , large oncosomes (1-10 μm) [35, 36] , matrix vesicles [37] , migrasomes [38] , exopheres (~4 μm), exomeres (~35 nm), and bacterial outer membrane vesicles (OMV) [39] . EVs are also classified by their sizes into small EVs (sEV: 30-500 nm) and large EVs (L-EV: > 1 µm) [35, 40] . These vesicles play basic roles in discarding molecules unfavorable for cells [41] , while also mediating intercellular communication by transferring their cargos to recipient cells or organs in local and/or distant tissues [42] . Among various concepts of EVs, oncosomes have been shown to promote processes in tumor progression such as epithelial-to-mesenchymal transition (EMT) by transferring oncogenic molecules [43] [44] [45] . In addition, the findings that enhancement of EMT properties was coupled with increased release of EVs [20, 46] prompted us to make a concept of EMT-coupled vesicle release.
Among a number of molecular cargos, HSPs are major signatures often found within sEV such as exosomes, ectosomes, and oncosomes [16] [17] [18] 25] . Indeed, sEV derived from oral cancer cells contained a 4 variety of HSPs, including HSP90α, HSP90β, TRAP1 (mitochondrial HSP90), HSP105, HSP70 (HSP72/HSPA1A and HSP70B'/HSPA6), GRP78/HSPA5 (ER chaperone), and heat shock cognate 70 (HSC70: essential for autophagy) [17] . Notably, two HSP90 isoforms-HSP90α and HSP90β were enriched in sEV derived from high metastatic cancer cells compared to low metastatic ones [17] . The high expression levels of HSP90α/β are correlated with poor prognosis in patients suffering from head and neck cancers [17] . A number of studies, including ours, have indicated that HSP90 is essential in stress resistance in cancer cells [16, [47] [48] [49] . Notably, HSP90α and its key co-chaperone CDC37 were highly expressed in resistant prostate cancer cells [18, 50] . However, less is known regarding stress-responsive co-release of EVs and HSP90 from the resistant cells. We have therefore addressed this deficiency in this study.
The growth of prostate cancers is often androgen-dependent, requiring factors such as testosterone and dihydrotestosterone (DHT) [51] . Therefore, androgen depletion therapy (ADT), also called hormone therapy is often effective in prostate cancers. However, some types of prostate cancer are resistant to ADT.
These castration-resistant prostate cancers (CRPC) are known as neuroendocrine tumors (NET), and this is also a phenotype found in aggressive pancreatic cancer [52] [53] [54] . Notably, tumorigenicity and epithelialto-mesenchymal transition (EMT) are key properties for recurrence and metastasis in such aggressive, resistant cancers [55, 56] . In the androgen insensitivity, intracellular kinase signaling pathways are given higher priorities required for tumor progression. Indeed, it has been shown that CDC37, the protein kinase-specialized (kinome) co-chaperone of HSP90, were highly expressed in the resistant prostate cancer cells [57] . CDC37 plays a fundamental role in chaperoning almost all members of the protein kinase family and participates in cancer by maintaining the activity of protein kinases involved in cell proliferation and transformation [58, 59] . These include tyrosine kinases such as Src [60] , and serine/threonine kinases in the Raf-ERK pathway [61] , Akt, the inhibitor of NF-κB kinase (IKK) [62] , and cyclin-dependent kinase 4 (CDK4) [63, 64] . CDC37 functions primarily in a complex with HSP90 to mediate the 3-dimensional (3D) folding and structural integrity of client proteins kinases [60, 65] . CDC37 is particularly significant in prostate cancer as its overexpression leads to spontaneous prostate carcinogenesis in transgenic mice [66] . It has also been suggested that the high levels of oncogenic proteins present in most cancers make them dependent on molecular chaperones, a state referred to as "chaperone addiction" [58] . Thus, because of their large protein clienteles, the CDC37-HSP90 axis offers a critical target for inactivating multiple oncogenic pathways. Consequently, the inhibition of HSP90 in cancer is currently a major area of research [67, 68] . However, less is known regarding the role of CDC37 in EV release and we have addressed this deficiency in this study.
In the present study, we therefore aimed (i) to reveal proteome signatures of EVs derived from resistant prostate cancer cells, (ii) to unveil stress-responsive vesicle release potentially coupled with resistant tumorigenicity in cancer.
Materials and Methods
Cell culture. PC-3, a CRPC cell line, and DU-145, a prostate adenocarcinoma cell line, were maintained in RPMI1640 medium with 5% to 10% FBS as described previously [18, 57, 69, 70] . RWPE1, a human normal prostate cell line, was maintained in keratinocyte serum-free medium (ThermoFisher, Waltham, MA) supplemented with recombinant human epidermal growth factor and bovine pituitary extract.
Heat shock stress. For HSS, the medium was replaced to incubated medium at 43℃ or 37℃ and then put in a water bath at 43℃ or 37℃, as described previously [23, 71] . After HSS, cells were washed with PBS (-) and cultured in serum-free media. Cellular photomicrographs were taken at 24 h after medium replacement by using Floid Cell Imaging Station (ThermoFisher).
Extracellular vesicle and non-EV fractions.
For HSS experiments, after the above-mentioned HS, cells were washed with PBS and cultured in serum-free media for 24 h and then conditioned media was collected. At the time of harvest, the numbers of cells were counted using Countess (ThermoFisher) and whole cell lysate was prepared as described below. Otherwise, cultured cells were washed with Hanks' balanced salt solution (HBSS), and then further cultured in serum-free medium for 1 or 2 days. EV fraction was prepared using a modified polymer-based precipitation (PBP) method. Briefly, the conditioned medium was centrifuged at 2,000 × g for 30 min at 4°C to remove cell debris. For studies of knockdown and EMT, the supernatant was filtered with a 0.2-µm syringe filter. Otherwise, the filter was not used. The supernatant was collected and centrifuged at 10,000 × g for 30 min at 4°C. The supernatant was collected and applied to an Amicon Ultra-15 Centrifugal Filter Device MW.100k (Merck, Kenilworth, NJ) to concentrate the pre-EV fraction to less than 1 ml and to separate non-EV soluble fraction. The passthrough was applied to an Amicon Ultra-4 Centrifugal Filter Device MW.10k (Merck) to concentrate the non-EV soluble fraction. Total Exosome Isolation Reagent (ThermoFisher) was applied to the pre-EV fraction and incubated overnight at 4 C. The precipitated EVs were collected by centrifugation at 10,000 × g for 60 min at 4 C. For biological assays, the EV fractions were eluted in 100 μl PBS (−). For protein assay, 10 × RIPA buffer containing 10% NP-40, 1% SDS, 5% deoxycholate in PBS (-), and a protease 6 inhibitor cocktail (Sigma) was added to the EV fraction, incubated on ice for 15 min. The EV-derived protein samples were quantified with a principle of bicinchoninic acid (BCA) method using Micro BCA protein assay system (ThermoFisher). EV protein concentrations per cell were calculated at the time points of harvest.
Mass spectrometry. EV fraction was incubated in the presence of 1% SDS and 2.5 mM Tris (2carboxyethyl)phosphine hydrochloride (ThermoFisher) for 10 min at 85C followed by alkylation with 12.5 mM iodoacetamide (Sigma) for 15 min at room temperature. Proteins were precipitated with acetone for 2 h at -30C and the resulting pellet was dispersed in 100 mM ammonium bicarbonate by ultrasonic treatment (three times for 30 s with intervals of 30 s) with a Bioruptor (Diagenode). The protein suspension was subjected to digestion with trypsin (1 g; Wako) for 14 h at 37C. Resulting peptides were analyzed by a QExactive mass spectrometer that was coupled with nano-LC (AdvanceLC, Michrom Inc.) via a nano-electrospray source with a column oven set at 37C (AMR Inc.). Samples were injected to pre-column (L-column micro: 0.3 mm inner diameter, 5 mm length; CERI, Japan) and separated by in-house made 20 cm column (inner diameter 100 m, 3 L-column; CERI, Japan) with a linear gradient (5-30% B for 110 min, 30-90% B for 1 min, and 90% B for 10 min, A: 0.1% formic acid, 2% acetonitrile, B: 0.1% formic acid, 99.9% acetonitrile) at a flow rate of 250 nl/min. The QExactive was operated in data-dependent acquisition mode. Scan ranges were set at m/z 375−1600 for MS spectra and at m/z 200−2000 for MS/MS spectra, respectively. MS spectra were acquired at a resolution of 70,000 at m/z 400 after accumulation to a target value of 1 × 10 6 with the maximum ion injection times for 60 msec.
Up to the top 10, most abundant ions with charge 2+ or 3+ from the survey scan were selected with an isolation window of 1.5 h and fragmented by HCD with normalized collision energies of 25. MS/MS spectra were acquired at a resolution of 17,500 at m/z 400 after accumulation to a target value of 5 × 10 4 with the maximum ion injection times for 120 msec. The acquired MS/MS spectra were analyzed by Proteome Discoverer 1.4 with the Mascot algorithm (ver. 2.6.0) using an IPI human database (ver. 3.8.7).
The search was performed with the following parameters: Trypsin was selected as an enzyme used, allowed a number of missed cleavages was set 3 and carbamidomethylation on Cys were selected as a fixed modification. Oxidized methionine was searched as variable modifications. Precursor mass tolerances were 10 ppm and tolerance of MS/MS ions was 0.02 Da. The second LC-MS/MS with or without HS was carried out as described [17, 72] .
Electron microscopy.
A 400-mesh copper grid coated with formvar/carbon films was hydrophilically treated. The EV suspension (5 to 10 μl) was placed on parafilm, and the grid was floated on the EV liquid 8 Basel, Switzerland) per well at a cell confluence level of 50-70%. The medium was changed at 16-20 hours after transfection. At 40-48 hours after transfection, 70 µl of the medium was aspirated, then 30 µl of Bright-Glo reagent (Promega, Madison, WI) was added and mixed by pipetting. Cells were incubated for 5 minutes at 37°C. The lysate (40 µl) was transferred to a 96-well white plate for measurement of luminescence.
RNA interference. We designed siRNA sequences targeting mRNA of CDC37, HSP90AA1 or HSP90AB1 (Table 1) . For targeting each mRNA, a mixture of two types of siRNA duplex was used. The control nontargeting siRNA was purchased from Nippon Gene. Cells were transfected with siRNA using Lipofectamine RNAi MAX (Thermo Fisher). For single or double knockdown, cells were cultured in a 6-cm dish and 27 pmol siRNA was transfected with 8 µl of Lipofectamine RNAi MAX per dish for 24 hours. The medium was replaced to serum-free fresh ones and the EV and whole cell lysate (WCL) were prepared at 48 hours post-transfection. For triple knockdown, electroporation-mediated transfection was optimized and performed as described previously [57, 76] . To optimize electroporation for each cell type, cells (1 × 10 5 to 1 × 10 6 cells), siRNA (40 pmol total), and serum-free medium were mixed to 100 µl total in a green cuvette with a 1-mm gap (NepaGene, Ichikawa, Tokyo) and set to NEPA21 Super Electroporator (NepaGene). Poring pulse was optimized between 100V and 300V for 2.5 or 5.0 msec pulse length twice with 50 msec interval between the pulses and 10% decay rate with + polarity, as shown in a supplemental figure. The transfer pulse condition was five pulses at 20V for 50 msec pulse length with 50 msec interval between the pulses and 40% decay rate with +/-polarity. After electroporation, cells were recovered in serum-contained media.
PC-3 (5 × 10 5 cells) was transfected with 40 pmol siRNA with poring pulse at 175V for 2.5 msec pulse length twice and then cultured for 4 days for western blotting. Alternatively, transfected PC-3 was cultured for 5 days and 1 × 10 6 cells were subcutaneously injected to each SCID mouse as described below.
Whole Cell Lysate. Cells were lysed as described previously [17, 57, 76, 77] Statistics. Data were expressed as the means ± SD unless otherwise specified. Statistical significance was calculated using GraphPad Prism (GraphPad, La Jolla, CA). Comparisons of 2 were done with an unpaired Student's t-test. Three or more mean values were compared using ANOVA Tukey's multiple comparisons test.
Results

The proteome of sEV released by PC-3 cells
To establish a protein signature of sEV released by the CRPC cells, we performed proteomic analysis of extracellular medium using LC-MS/MS. More than 700 protein species were thus identified, including molecular chaperones (total score: 795.5) such as HSP90α and Hsp90β, extracellular signaling proteins Table 2 ).
We next examined whether HSP90α could be altered in cells and EVs or released in free form upon proteotoxic damage exerted by HSS at 43℃. HSP90α was abundantly released with EVs as well as non-EV extracellular HSP90 upon HSS for 1.5 or 3 hours (plus 24 hours recovery), while intracellular HSP90α was also increased (Fig. 1B) . As a control, we examined CD9 in the HSS study. Vesicular CD9 was increased upon the HSS, while intracellular levels decreased in the CRPC cells, suggesting that cellular CD9 was transmitted to EVs upon HSS.
These findings indicate that HSP90α was released with EVs in response to proteotoxic stress, while non-vesicular HSP90α was also released in response to the HSS. 
Stress triggered vesicle release (200-500 nm) and cell morphological changes.
We next determined whether the size and morphology of EVs released by the CRPC cells could be altered by HSS. Indeed, the size of EVs released from PC-3 cells without HSS was between 50 nm and 200 nm, while larger EVs sized between 200 nm and 500 nm increased in the medium upon HSS for 30 min, 1.5 hours, and 3 hours ( Fig. 2 A, B, C, D) . The morphologies of the EVs corresponded basically to a cuplike shape, although the detailed shapes were various ( Fig. 2A) . The prototypical EVs found under TEM were in a cup-like shape with clear walls potentially composed of a lipid bilayer, although the thickness of the EV walls varied ( Fig. 2A a) . The wall of an EV was partially thick, which may be associated with another particle ( Fig. 2A b) . Membrane deformation was also seen in some EVs ( Fig. 2A c) . Crescent shapes are reminiscent of membrane breakage of EVs ( Fig. 2A d) . These data suggested that the EVs of
50-200 nm were released from PC-3 cells without HSS, whereas the cells additionally released the larger
EVs of 200-500 nm upon stress, the stressome.
Along with the release of the stressome, the morphology of PC-3 cells was altered after HSS ( Fig. 2E) .
The rates of round-shaped cells and cells with projections (or spindle shape) were significantly increased after HSS (Fig. 2 E, F, G) . These data suggested that cells could lose intercellular adhesion and junction under stress.
These data suggested that stressome release was coupled with cell morphological changes.
EVs (200-500 nm) were co-released with LDH upon membrane damaging stress
Membrane deformation and break of EVs were potentially induced by the HSS. The membrane deformation of EVs, as well as cells, could trigger the release of HSP90 from the cells and EVs. In order to establish the stress-responsive release of EVs, we next measured the protein concentration of EVs altered by the stress. EV release was significantly increased upon HSS in terms of protein concentration (Fig. 3A) .
We next hypothesized that cell stress could damage cellular membrane permitting intracellular molecules such as HSPs and lactate dehydrogenase (LDH) to leak, while EVs such as ectosomes could be released by a physiological mechanism. To verify this, we next measured extracellular LDH released from the CRPC cells upon HSS. The release of LDH was increased by HSS for 3 hours as compared to non-heated cells ( Fig.   3 B-D). Heat shock, as well as serum starvation stress for 24 hours, increased the release of LDH ( Fig. 3 C, D).
These results indicated that HSS induced the release of LDH from the CRPC cells potentially through membrane damage of the cells. sEV and HSP90 could be co-released with LDH upon the membrane damage caused by HSS. CDC37 is a molecular chaperone that regulates the folding of kinases and nuclear receptors in association with HSP90. We therefore examined the potential role of this co-chaperone in the release of EVs. Many members of HSP family are stress-responsive, i.e. characteristically inducible by heat shock, but also by hypoxia, and starvation stress. However, it has not been fully established whether CDC37 could be stress-inducible or not. We next examined whether CDC37 could be transcriptionally inducible by HSS and involved in the release of EVs. We found a heat shock element (HSE) in the promoter region of human CDC37 gene ( Fig. 4 A, B) . The consensus HSE sequence is 5'-GAAxxTCCxxGAA-3' while the HSE in the -380 position in the human CDC37 promoter is 5'-GAAagTCCgaGgA-3'. To examine whether the CDC37 promoter could be regulated by heat shock factor 1 (HSF1), we performed the reporter assay using the CDC37 promoter-luciferase constructs. We here used DU-145 prostate adenocarcinoma cells, in which endogenous CDC37 level was not fully induced as compared to the PC-3 cells. The CDC37 promoter (500+utr) containing an HSE (-380) was activated by HSF1 overexpression in DU-145 cells, whereas dominant-negative HSF1 (DN-HSF1) failed to activate the CDC37 promoter ( Fig. 4 C, D) . Moreover, another CDC37 promoter construct (200+utr) without HSE did not respond to HSF1 overexpression.
These data indicated that HSF1 could mediate cell stress signal to the CDC37 gene.
We next examined whether CDC37, HSP90, and CD9 are inducible by HSS in PC-3 cells. As expected, CDC37 was induced by HSS (43℃, 30 min), but not found in either the extracellular or non-vesicular fractions (Fig. 4E, top) . HSP90α, a known inducible type of HSP, was increased by HSS intracellularly, in EVs, and in the non-vesicular extracellular fraction (Fig. 4E, second raw) . HSP90β, the constitutively expressed HSP90 ortholog was increased in the EV fraction upon the HSS, while intracellular HSP90β was decreased, suggesting that HSP90β could be transmitted from the cells to EV fraction upon the HSS (Fig.   4E , third raw). CD9 was increased in the cells and in the EV fraction upon the HSS (Fig. 4E, fourth raw) .
These data indicated that CD9-positive exosomes could be secreted from cells upon HSS coordinately with increased CDC37.
These data prompted us to hypothesize that CDC37, although not secreted itself, could be involved in the secretion of CD9-positive exosomes. To verify this hypothesis, we next asked whether the CD9 levels in the EV fraction could be altered by CDC37 knockdown using siRNA. CDC37 knockdown markedly decreased the CD9 level in the EV fraction (Fig. 4F) . Coordinately, EV protein concentration per cell was significantly decreased by CDC37 knockdown as compared to the control siRNA condition (Fig. 4G ).
Cellular protein concentration per cell was also significantly decreased by CDC37 knockdown.
These data suggested that CDC37 was essential for CD9-exosome release and for proteostasis in the CRPC cells. CDC37 is essential for EMT in the CRPC cells.
The coupling of vesicle release and cell morphological changes upon stress indicated that oncosomes could promote EMT as suggested in Fig. 2 . We next aimed to establish whether PC-3-derived EVs could alter EMT properties in the normal prostate epithelial cell line RWPE1. E-cadherin, an established epithelial marker, was decreased by the addition of PC-3-derived EVs in a concentration-dependent manner (0, 5, 10, 25 or 50 g/ml) (Fig. 5A ). In contrast, N-cadherin, an established mesenchymal marker, was increased by the addition of PC-3-derived EVs in a concentration-dependent manner. These data therefore suggested that PC-3-derived EVs could initiate EMT in the prostate epithelial cells.
We next examined whether both CDC37 and HSP90α could be involved in EMT properties in PC-3 cells. We here investigated the vimentin level, a well-established mesenchymal marker. The knockdown of CDC37 markedly decreased vimentin and increased E-cadherin levels in the CRPC cells ( Fig. 5B ),
indicating that CDC37 is an essential factor in EMT. Unlike CDC37, knockdown HSP90α did not decrease vimentin and did increase E-cadherin.
We next examined whether CDC37 and HSP90α could be involved in the release of EVs from PC-3 cells. The knockdown of CDC37 significantly decreased the fraction of EV protein compared with cellular protein concentration, suggesting that EV release was inhibited by CDC37 knockdown (Fig. 5C ). In contrast, knockdown of HSP90α did not decrease EV release.
These data indicated that CDC37 was essential for CD9-exosome release and for EMT in prostate cancer cells.
Triple targeting of CDC37, HSP90α, and HSP90β declines the tumorigenicity of CRPC in vivo.
We have experienced that knockdown of a chaperone could often trigger the compensatory induction of another chaperone. We therefore next examined double knockdown and triple knockdown of the chaperone trio-CDC37, HSP90α, and HSP90β. Each combination of siRNA successfully reduced their respective targets, while triple siRNA combination markedly reduced the CDC37, HSP90α, and HSP90β trio ( Fig. 5D ). Previous studies have shown that PC-3, a CRPC cell line, was the most tumorigenic prostate cancer cell line as compared to the other established prostate carcinoma cell lines. We next examined whether the triple knockdown of the chaperone trio (CDC37, HSP90α, HSP90β) could alter in vivo tumorigenesis of the CRPC cells. The triple knockdown of the chaperone trio markedly inhibited in vivo tumorigenesis of PC-3 cells (Fig. 5E ).
These results indicated that members of the chaperone trio (CDC37, HSP90α, HSP90β) were complementary to each other and essential for tumorigenicity of the resistant prostate cancer cells. 
Discussion
Cell extrinsic molecules secreted by both tumor and infiltrating normal cells may play key roles in conditioning the tumor environment and enhancing malignancy. For instance, infiltrating macrophages and fibroblasts may supply key growth factors and ECM molecules enhancing growth and metastasis [78] [79] [80] . Tumors may also condition their own environments with molecules such as HSPs to supply essential chaperones to recipient cells and trigger receptor-mediated signaling [16, 81] . However, the exact details of the tumor chaperone network are not yet defined. Our study demonstrated that HSP90 and CDC37 are essential for a key component of the network, stressome release which permits the exit of HSPs and promotes tumor progression in resistant prostate cancer. The release of EVs and HSP90 from the CRPC cells was a major aspect of the resistance-associated secretory phenotype (RASP). Moreover, we show intracellular CDC37 to be essential for EMT-coupled EV release from CRPC cells, which may constitute a key first step to understanding the mechanisms underlying HSP-loaded EV secretion. There are more than ten co-chaperones of HSP90, which individually carry out distinct cooperative roles with HSP90 in cells [82] . CDC37 is a definitive kinome chaperone assisting in the folding of protein kinases such as SRC, many receptor tyrosine kinases (RTK), their downstream Ras/Raf/MEK/ERK signaling pathway, and PI3K-AKT signaling pathway, which promote EMT [83] [84] [85] [86] . Among such key kinases, a recent study showed that SRC in endosomal membranes promoted exosome secretion and tumor progression [87] . Moreover, activation of the epidermal growth factor receptor (EGFR) promoted the secretion of EGFR-rich EVs, whose transmission to recipient cells promoted EMT and metastasis [45, [88] [89] [90] [91] . LRP1/CD91 is potentially another such an RTK, a receptor whose tyrosine residue in the intracellular domain is phosphorylated by extracellular HSP90 and activates MEK-ERK signaling pathway [92] . CDC37 could positively regulate EMT and exosome release through permitting the function of these protein kinases. Consistently, recent studies have shown that EMT in cancer cells was often coupled with exosome release and drug resistance [20, 93, 94] .
Our studies also touch upon the induced release of HSP90 in the resistant prostate cancer cells. A number of studies, including ours, have indicated that HSP90 is essential in stress resistance in cancer cells [16] [17] [18] 47, 49] . Notably, extracellular HSP90 plays key roles in tumor progression and metastasis as well as immune surveillance [25] . However, mechanisms by which HSP90 is released from cells had not well-investigated before our study. We demonstrated HSP90α to be robustly inducible by HSS and efficiently released as a cargo of EV as well as in the form of EV-free HSP90. In contrast, the HSP90β ortholog was not markedly inducible but was transmitted to EVs upon HSS and barely dissolved in the extracellular fluid. Notably, LDH, GAPDH, HSP90α, and ectosomes/stressome were co-released from cells upon HSS, suggesting that cellular membrane, as well as vesicular membranes, were damaged by the stress. Indeed, extracellular HSPs have been known to exhibit the functions of DAMPs. Moreover, membrane-bound HSPs can be associated with stress-responsive EVs [25] . Along with such released structures, sEV (200-500 nm) were co-released upon HSS, while membrane damage of sEV was also observed upon HSS (Fig. 3 ). Production of ectosomes (100-500 nm) requires budding and shedding of the cell membrane, which can create membrane damage on cells and vesicles. Moreover, it has been shown that cell motility and stem cell properties induced by the EMT required destabilization of lipid rafts [95] . Therefore, it is conceivable that heat shock triggers the co-release of ectosomes, HSP90, and LDH through membrane damage and destabilization of lipid rafts. A recent study showed that HSP90 mediated membrane deformation and exosome release [96] . However, in our study, knockdown of HSP90 did not decrease the release of vesicles, while, as mentioned above, knockdown of CDC37 significantly decreased the release of EVs, including CD9-exosomes, from the CRPC cells. Therefore, it was conceivable that the chaperone activity of CDC37 was essential for the release of sEV. It is also clear that the properties of 3D tumors in vivo might be largely different in many aspects from 2D-cultured cells in vitro. Single targeting of CDC37 did not inhibit in vivo tumorigenicity, while triple targeting of CDC37/HSP90α/HSP90β markedly inhibited tumorigenicity of CRPC cells. Consistently, HSP90α was markedly released from 3D tumoroids of PC-3 cells, which resemble a miniaturized tumor in vitro. Thus, the chaperone trio composed of CDC37 and HSP90α/β was crucial for tumorigenicity of CRPC cells. Notably, the tumorigenicity of CRPC cells is a key property for recurrence and metastasis in this type of prostate cancer. In the androgen insensitivity, intracellular kinase signaling pathways can be of higher priority required for tumor progression. This logic is consistent with elevated expression of CDC37, a kinome chaperone, in CRPC as compared to prostate adenocarcinoma and with the anti-tumor effect of the triple chaperone depletion.
Our data also indicated that HSF1, a mediator of the stress response, positively regulates CDC37 gene expression. We recently demonstrated that myeloid zinc finger 1 (MZF1) and SCAND1 reciprocally regulated CDC37 gene expression in prostate cancer. In this study, a gain of MZF1, as well as a loss of SCAND1, were crucial for CDC37 expression. Intracellular matrix metalloproteinase (MMP) 3, a moonlighting transcription factor, also cooperated with HSF1-mediated stress response [71, 72, 97] . Thus, HSF1 can coordinately activate the CDC37 gene along with other transcription factors, while especially playing a key role in stress response and resistance. Indeed, the overexpression of a DN-HSF1 construct inhibited aneuploidy in prostate carcinoma cells [98] . Thus, HSF1 activation of CDC37 could be crucial for exosome release as well as EMT.
In conclusion, CDC37 and HSP90 are essential for stressome release and EMT-associated tumor progression in resistant prostate cancer. The release of sEV and HSP90 is a major aspect of RASP. Of note, intracellular CDC37 is essential for EMT-coupled EV release from the resistant prostate cancer cells.
Future studies are aimed at defining the exact role of CDC37 in the formation and release of tumor EVs.
Author Contributions: TE conceptualized, designed and managed the study, acquired funding, performed heat shock experiments, sampling, promoter analysis, reporter gene assay, animal experiments, and wrote the manuscript. CS performed heat shock experiments, western blotting, TEM, particle diameter analysis, LDH assay, and statistical analysis and wrote the method section. KOn 
